- In February 2024, Iridex Corporation was granted a European patent, EP 3009093, for its innovative short-pulse laser technology, particularly its MicroPulse devices. This patented technology delivers precise, brief laser pulses to minimize retinal damage and vision loss, issues common with traditional LASER treatments. Clinical trials have demonstrated its safety and effectiveness in various eye procedures, including those for retina and glaucoma, marking a significant advancement in medical laser therapy
- In May 2023, Norlase secured USD 11 million USD in its largest investment round, led by London-based West Hill Capital. This funding follows the company’s recent achievements, including FDA clearance and CE mark approval for its ECHO pattern laser. With the additional funds, Norlase plans to accelerate the production of the ECHO laser and other advanced laser-based cancer therapies, aiming to revolutionize cancer treatment with cutting-edge technology
- In April 2023, Lumibird Medical launched two next-generation lasers, Tango Neo and Ultra Q Reflex Neo. These new products feature advanced capabilities, expanding the company's product portfolio in the eye care sector. With these innovations, Lumibird aims to enhance the precision and effectiveness of laser treatments, positioning itself at the forefront of medical laser technology while addressing diverse patient needs in ophthalmology
- In April 2023, Iridex Corporation introduced the PASCAL platform, a next-generation device with advanced scanning capabilities. This launch marked a significant expansion of Iridex's product portfolio. The PASCAL system is designed to provide higher precision and efficiency in laser treatments for ophthalmic conditions, reinforcing the company's position as a leader in laser-based medical devices, particularly for retinal and glaucoma treatments
- In October 2022, A USD 2100.73 billion funding boost from U.K. Research and Innovation (UKRI) was allocated to establish the Ion Therapy Research Facility (ITRF). This facility, in collaboration with Imperial College London, aims to enhance ion beam therapy for cancer treatment. The ITRF will focus on developing more affordable, versatile ion beam therapies, combining cutting-edge physics research with drug treatments to offer more effective cancer treatments
- In October 2022, Dexcom began the global rollout of its G7 continuous glucose monitoring (CGM) system in the U.K., Ireland, Germany, Austria, and Hong Kong. The G7 system promises quicker power-up times, a smaller form factor, and an improved mobile application compared to previous models. Although the U.S. launch was delayed until late 2022, the global expansion marked a significant step forward in advancing diabetes management with this more user-friendly technology
Frequently Asked Questions
The market is segmented based on Segmentation, By Type (Diode Lasers, Solid State Lasers, Liquid Lasers, Semiconductor Lasers, Gas Lasers, Dye Lasers and Others), Application (Dermatology and Aesthetics, Surgery, Gynaecology, Dental, Urology, Ophthalmology, Cardiovascular and Others), End User (Hospitals, Specialized Clinics, Ambulatory Surgical Centres and Others) – Industry Trends and Forecast to 2032
.
The Global Laser Therapy Market size was valued at USD 5.22 USD Billion in 2024.
The Global Laser Therapy Market is projected to grow at a CAGR of 5.4% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
